pharma news today glp-1 obesity A network meta-analysis backed weight-loss benefits with several receptor agonists, with less certainty for newer-generation agents. Read more at the link in bio GLP-1 Agonists Market Report 2025-2033,

That said, these studies are still limited

Patients with type 2 diabetes in the SURPASS clinical trials lost between 12lb and 25lb on average

Alcohol consumption, particularly frequent binge drinking, impairs metabolic function and increases inflammation, both of which reduce GLP-1 medication effectiveness

[DOI] [PMC free article] [PubMed] [Google Scholar] 72.Flak JN, Patterson CM, Garfield AS, DAgostino G, Goforth PB, Sutton AK, et al

Ian Thompson takes us through the recent history of diabetes and obesity therapeutics, the innovative peptide hormone molecules that have reached the market over the past decades and the equally innovative devices developed to deliver them